Anti-Inflammatory Biologics Global Market Report 2025
상품코드:1810827
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
항염증 생물학적 제제 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년 연평균 성장률(CAGR)은 9.0%로 1,662억 8,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 생물학적 제제의 채택 증가, 표적치료에 대한 수요 증가, 장기 관해에 대한 환자 선호도 증가, 질병 모니터링을 위한 바이오마커의 사용 확대, 맞춤형 의료에 대한 수요 증가에 기인하는 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 생물학적 제제 개발의 진전, 염증에 대한 경구용 생물학적 제제의 출현, 기술 주도형 약물전달 시스템, 바이오시밀러의 발전, 진단 도구의 개선 등이 있습니다.
관절염의 유병률 증가는 항염증 생물학적 제제 시장의 성장을 견인할 것으로 예상됩니다. 관절염은 하나 또는 여러 관절의 염증과 부종, 통증, 뻣뻣함, 움직임의 제한을 동반하며, 나이가 들면서 악화되는 경우가 많습니다. 관절염 환자의 증가는 비만율의 증가와 밀접한 관련이 있는데, 이는 과도한 체중이 관절에 스트레스를 주어 염증과 퇴행을 유발하기 때문입니다. 항염증 생물학적 제제는 중등도에서 중증의 관절염 환자를 위해 염증을 억제하고, 관절 손상을 지연시키고, 증상을 완화하고, 신체 기능과 삶의 질을 개선하기 위해 면역 체계의 특정 부분을 표적으로 삼아 작용합니다. 예를 들어, 2023년 3월 영국의 Office for Health Improvement and Disparities는 2022년 16세 이상 인구의 17.6%가 관절염이나 지속적인 허리 및 관절 문제와 같은 장기적인 근골격계 질환을 앓고 있으며, 이는 2021년 17.0%에서 증가한 수치라고 보고했습니다. 라고 보고했습니다. 이러한 관절염 유병률의 증가는 시장 확대의 원동력이 되고 있습니다.
항염증 생물학적 제제 시장의 각 업체들은 부작용을 최소화하면서 만성 염증성 질환을 보다 정확하게 치료하기 위해 인터류킨-6(IL-6) 수용체 길항제 등 첨단 치료제를 개발하고 있습니다. IL-6 수용체 길항제는 IL-6 수용체를 억제하는 생물학적 제제로 류마티스 관절염 등의 염증과 면역반응을 억제합니다. 예를 들어, 미국 생명공학 기업 리제네론 파마슈티컬스(Regeneron Pharmaceuticals Inc.)는 2023년 2월 부신피질 스테로이드가 충분히 효과가 없는 류마티스성 다발성 근육통(PMR) 환자를 위한 최초의 생물학적 제제로 케브잘라(Kebzala)의 FDA 승인을 획득했습니다. 케브자라는 완전 인간형 단클론항체로 IL-6 수용체를 차단하여 주로 노인에게 근육통과 경직을 유발하는 질환인 PMR과 관련된 염증을 억제합니다. 케브자라는 장기간 사용 시 골다공증, 당뇨병 등의 위험을 수반하는 기존 스테로이드제와는 달리, 타겟을 좁히고 스테로이드를 보존하는 대안을 제공함으로써 환자의 예후를 개선하고 장기적인 안전성을 도모합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 항염증 생물학적 제제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 항염증 생물학적 제제 시장 : 성장률 분석
세계의 항염증 생물학적 제제 시장 실적 : 규모와 성장, 2019-2024
세계의 항염증 생물학적 제제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 항염증 생물학적 제제 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 항염증 생물학적 제제 시장 : 약물 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
종양괴사인자 억제제
인터류킨 억제제
B세포 억제제
T세포 억제제
기타 약물 클래스
세계의 항염증 생물학적 제제 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
주사
정맥내
피하
세계의 항염증 생물학적 제제 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
류마티스 관절염
염증성 장질환
건선
기타 용도
세계의 항염증 생물학적 제제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
기타 유통 채널
세계의 항염증 생물학적 제제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
클리닉
재택 케어 설정
조사·학술기관
세계의 항염증 생물학적 제제 시장 : 하위 세분화 종양괴사인자 억제제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
Adalimumab
Infliximab
Etanercept
Golimumab
Certolizumab pegol
세계의 항염증 생물학적 제제 시장 : 하위 세분화 인터류킨 억제제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
인터류킨-1 억제제
인터류킨-6 억제제
인터류킨-12 또는 23 억제제
인터류킨-17 억제제
인터류킨-23 억제제
세계의 항염증 생물학적 제제 시장 : 하위 세분화 B세포 억제제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
Rituximab
Ocrelizumab
Ofatumumab
세계의 항염증 생물학적 제제 시장 : 하위 세분화 T세포 억제제(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
Abatacept
Alefacept
세계의 항염증 생물학적 제제 시장 : 하위 세분화 기타 약물 클래스(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
야누스 키나아제 억제제
포스포디에스테라제 4 억제제
스핑고신 1-인산 수용체 조절제
항IgE 항체 및 기타 생물학적 제제
제7장 지역별·국가별 분석
세계의 항염증 생물학적 제제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 항염증 생물학적 제제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
항염증 생물학적 제제 시장 : 경쟁 구도
항염증 생물학적 제제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Bristol-Myers Squibb
AstraZeneca PLC
Novartis AG
GSK plc
Eli Lilly and Company
Gilead Sciences Inc
Amgen Inc.
Regeneron Pharmaceuticals Inc
Biogen Inc.
UCB S.A
UCB S.A./N.V
Swedish Orphan Biovitrum AB
Almirall S.A.
Evotec SE
Hansa Biopharma AB
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
항염증 생물학적 제제 시장 2029 : 새로운 기회를 제공하는 국가
항염증 생물학적 제제 시장 2029 : 새로운 기회를 제공하는 부문
항염증 생물학적 제제 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Anti-inflammatory biologics are therapeutic drugs derived from living organisms that specifically target elements of the immune system to reduce inflammation. They are widely used to treat chronic inflammatory diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease by inhibiting cytokines or immune cells responsible for triggering inflammation.
The main drug classes of anti-inflammatory biologics include tumor necrosis factor inhibitors, interleukin inhibitors, B-cell inhibitors, T-cell inhibitors, and others. Tumor necrosis factor inhibitors are biologic drugs that block the activity of tumor necrosis factor-alpha, a substance in the body that causes inflammation, helping to alleviate symptoms in autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease. These medications are administered via various routes, including oral, injection, intravenous, and subcutaneous methods. They are commonly used for applications such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, among others, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and more. The end users of these biologics include hospitals, clinics, home care settings, and research and academic institutions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The anti-inflammatory biologics market research report is one of a series of new reports from The Business Research Company that provides anti-inflammatory biologics market statistics, including anti-inflammatory biologics global market size, regional shares, competitors with anti-inflammatory biologics market share, detailed anti-inflammatory biologics market segments, market trends and opportunities, and any further data you may need to thrive in the anti-inflammatory biologics industry. The anti-inflammatory biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The anti-inflammatory biologics market size has grown strongly in recent years. It will grow from $108.11 billion in 2024 to $118.02 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth during the historic period can be attributed to the rising prevalence of arthritis, increased awareness of autoimmune diseases, the growing introduction of new biologics, expanding healthcare infrastructure, and a rise in regulatory approvals.
The anti-inflammatory biologics market size is expected to see strong growth in the next few years. It will grow to $166.28 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to the increasing adoption of biologics, rising demand for targeted therapies, growing patient preference for long-term remission, expanded use of biomarkers for disease monitoring, and the increasing demand for personalized medicine. Key trends expected during this period include advancements in biologic drug development, the emergence of oral biologics for inflammation, technology-driven drug delivery systems, progress in biosimilars, and improvements in diagnostic tools.
The increasing prevalence of arthritis is expected to drive the growth of the anti-inflammatory biologics market. Arthritis involves inflammation or swelling in one or more joints, resulting in pain, stiffness, and limited movement, often worsening with age. The rise in arthritis cases is largely linked to increasing obesity rates, as excess weight adds stress to the joints, causing inflammation and degeneration. Anti-inflammatory biologics work by targeting specific parts of the immune system to reduce inflammation, slow joint damage, alleviate symptoms, and enhance physical function and quality of life for individuals with moderate to severe arthritis. For example, in March 2023, the UK's Office for Health Improvement and Disparities reported that in 2022, 17.6% of people aged 16 and older had a long-term musculoskeletal condition like arthritis or persistent back or joint issues, up from 17.0% in 2021. This growing prevalence of arthritis is driving market expansion.
Companies in the anti-inflammatory biologics market are developing advanced treatments such as interleukin-6 (IL-6) receptor antagonists to more precisely target chronic inflammatory diseases while minimizing side effects. IL-6 receptor antagonists are biologic drugs that inhibit the IL-6 receptor, reducing inflammation and immune response in conditions such as rheumatoid arthritis. For instance, in February 2023, Regeneron Pharmaceuticals Inc., a US biotechnology firm, received FDA approval for Kevzara as the first biologic specifically indicated for patients with polymyalgia rheumatica (PMR) who do not respond adequately to corticosteroids. Kevzara is a fully human monoclonal antibody that blocks the IL-6 receptor to decrease inflammation associated with PMR, a disease causing muscle pain and stiffness, mainly in older adults. Unlike traditional steroids, which carry risks like osteoporosis and diabetes with long-term use, Kevzara offers a targeted, steroid-sparing alternative that promotes better patient outcomes and long-term safety.
In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition aims to strengthen Amgen's position in innovative treatments for serious illnesses by expanding its portfolio in rare and autoimmune diseases, accelerating growth, and extending its reach to more patients worldwide with first-in-class therapies. Horizon Therapeutics plc, based in Ireland, focuses on developing several anti-inflammatory biologics.
Major players in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc., Regeneron Pharmaceuticals Inc, Biogen Inc., UCB S.A, UCB S.A./N.V, Swedish Orphan Biovitrum AB, Almirall S.A., Evotec SE, and Hansa Biopharma AB.
North America was the largest region in the anti-inflammatory biologics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in anti-inflammatory biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the anti-inflammatory biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The anti-inflammatory biologics market consists of sales of adalimumab, etanercept, infliximab, ustekinumab, and secukinumab. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Anti-Inflammatory Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on anti-inflammatory biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for anti-inflammatory biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anti-inflammatory biologics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Tumor Necrosis Factor Inhibitors; Interleukin Inhibitors; B-Cell Inhibitors; T-Cell Inhibitors; Other Drug Classes
2) By Route Of Administration: Oral; Injection; Intravenous; Subcutaneous
3) By Application: Rheumatoid Arthritis; Inflammatory Bowel Disease; Psoriasis; Other Applications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
5) By End-Users: Hospital; Clinics; Home Care Settings; Research And Academic Institutes
2) By Interleukin Inhibitors: Interleukin-1 Inhibitors; Interleukin-6 Inhibitors; Interleukin -12 Or 23 Inhibitors; Interleukin -17 Inhibitors; Interleukin -23 Inhibitors
3) By B-Cell Inhibitors: Rituximab; Ocrelizumab; Ofatumumab
4) By T-Cell Inhibitors: Abatacept; Alefacept
5) By Other Drug Classes: Janus Kinase Inhibitors; Phosphodiesterase-4 Inhibitors; Sphingosine 1-Phosphate Receptor Modulators; Anti-IgE And Other Biologics
Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Roche Holding AG; AbbVie Inc; Sanofi S.A; Bristol-Myers Squibb; AstraZeneca PLC; Novartis AG; GSK plc; Eli Lilly and Company; Gilead Sciences Inc; Amgen Inc.; Regeneron Pharmaceuticals Inc; Biogen Inc.; UCB S.A; UCB S.A./N.V; Swedish Orphan Biovitrum AB; Almirall S.A.; Evotec SE; Hansa Biopharma AB.
3. Anti-Inflammatory Biologics Market Trends And Strategies
4. Anti-Inflammatory Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Anti-Inflammatory Biologics Growth Analysis And Strategic Analysis Framework
5.1. Global Anti-Inflammatory Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Anti-Inflammatory Biologics Market Growth Rate Analysis
5.4. Global Anti-Inflammatory Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Anti-Inflammatory Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Anti-Inflammatory Biologics Total Addressable Market (TAM)
6.1. Global Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
B-Cell Inhibitors
T-Cell Inhibitors
Other Drug Classes
6.2. Global Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injection
Intravenous
Subcutaneous
6.3. Global Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rheumatoid Arthritis
Inflammatory Bowel Disease
Psoriasis
Other Applications
6.4. Global Anti-Inflammatory Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.5. Global Anti-Inflammatory Biologics Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Clinics
Home Care Settings
Research And Academic Institutes
6.6. Global Anti-Inflammatory Biologics Market, Sub-Segmentation Of Tumor Necrosis Factor Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adalimumab
Infliximab
Etanercept
Golimumab
Certolizumab pegol
6.7. Global Anti-Inflammatory Biologics Market, Sub-Segmentation Of Interleukin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interleukin -1 Inhibitors
Interleukin -6 Inhibitors
Interleukin -12 Or 23 Inhibitors
Interleukin -17 Inhibitors
Interleukin -23 Inhibitors
6.8. Global Anti-Inflammatory Biologics Market, Sub-Segmentation Of B-Cell Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rituximab
Ocrelizumab
Ofatumumab
6.9. Global Anti-Inflammatory Biologics Market, Sub-Segmentation Of T-Cell Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Abatacept
Alefacept
6.10. Global Anti-Inflammatory Biologics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Janus Kinase Inhibitors
Phosphodiesterase-4 Inhibitors
Sphingosine 1-Phosphate Receptor Modulators
Anti-IgE And Other Biologics
7. Anti-Inflammatory Biologics Market Regional And Country Analysis
7.1. Global Anti-Inflammatory Biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Anti-Inflammatory Biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Anti-Inflammatory Biologics Market
9.1. China Anti-Inflammatory Biologics Market Overview
9.2. China Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Anti-Inflammatory Biologics Market
10.1. India Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Anti-Inflammatory Biologics Market
11.1. Japan Anti-Inflammatory Biologics Market Overview
11.2. Japan Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Anti-Inflammatory Biologics Market
12.1. Australia Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Anti-Inflammatory Biologics Market
13.1. Indonesia Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Anti-Inflammatory Biologics Market
14.1. South Korea Anti-Inflammatory Biologics Market Overview
14.2. South Korea Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Anti-Inflammatory Biologics Market
15.1. Western Europe Anti-Inflammatory Biologics Market Overview
15.2. Western Europe Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Anti-Inflammatory Biologics Market
16.1. UK Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Anti-Inflammatory Biologics Market
17.1. Germany Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Anti-Inflammatory Biologics Market
18.1. France Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Anti-Inflammatory Biologics Market
19.1. Italy Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Anti-Inflammatory Biologics Market
20.1. Spain Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Anti-Inflammatory Biologics Market
21.1. Eastern Europe Anti-Inflammatory Biologics Market Overview
21.2. Eastern Europe Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Anti-Inflammatory Biologics Market
22.1. Russia Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Anti-Inflammatory Biologics Market
23.1. North America Anti-Inflammatory Biologics Market Overview
23.2. North America Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Anti-Inflammatory Biologics Market
24.1. USA Anti-Inflammatory Biologics Market Overview
24.2. USA Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Anti-Inflammatory Biologics Market
26.1. South America Anti-Inflammatory Biologics Market Overview
26.2. South America Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Anti-Inflammatory Biologics Market
27.1. Brazil Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Anti-Inflammatory Biologics Market
28.1. Middle East Anti-Inflammatory Biologics Market Overview
28.2. Middle East Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Anti-Inflammatory Biologics Market
29.1. Africa Anti-Inflammatory Biologics Market Overview
29.2. Africa Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Anti-Inflammatory Biologics Market Competitive Landscape And Company Profiles
